Ballard-Croft Cherry, Wang Dongfang, Rosenstein Kyle, Wang Jingkun, Pollock Robert, Morris J Ann, Zwischenberger Joseph B
Department of Surgery, University of Kentucky College of Medicine, Lexington, Ky.
Department of Surgery, University of Kentucky College of Medicine, Lexington, Ky.
J Thorac Cardiovasc Surg. 2014 Nov;148(5):2360-6. doi: 10.1016/j.jtcvs.2014.04.045. Epub 2014 May 5.
Since hyperthermia selectively kills lung cancer cells, we developed a venovenous perfusion-induced systemic hyperthermia system for advanced lung cancer therapy. Our objective was to test the safety and accuracy of our venovenous perfusion-induced systemic hyperthermia system in 5-day sheep survival studies, following Good Laboratory Practice standards.
Our venovenous perfusion-induced systemic hyperthermia system, which included a double-lumen cannula (Avalon Elite, Rancho Dominguez, Calif), a centrifugal pump (Bio-Pump 560; Medtronic Inc, Minneapolis, Minn), a heat exchanger (BIOtherm; Medtronic Perfusion Systems, Brooklyn Park, Minn), and a heater/cooler (modified Blanketrol IIIl Cincinnati Subzero, Cincinnati, Ohio), was tested in healthy adult sheep (n=5). The perfusion circuit was primed with prewarmed Plasma-Lyte A (Baxter Healthcare Corp, Deerfield, Ill) and de-aired. Calibrated temperature probes were placed in the right and left sides of the nasopharynx, bladder, and blood in/out tubing in the animal. The double-lumen cannula was inserted through the jugular vein into the superior vena cava, with the tip in the inferior vena cava.
Therapeutic core temperature (42°C-42.5°C), calculated from the right and left sides of the nasopharynx and bladder temperatures, was achieved in all sheep. Heating time was 21±5 minutes. Therapeutic core temperature was maintained for 120 minutes followed by a cooling phase (35±6 minutes) to reach baseline temperature. All sheep recovered from anesthesia with spontaneous breathing within 4 hours. Arterial, pulmonary, and central venous pressures were stable. Transient increases in heart rate, cardiac output, and blood glucose occurred during hyperthermia but returned to normal range after venovenous perfusion-induced systemic hyperthermia termination. Electrolytes, complete blood counts, and metabolism enzymes were within normal to near normal range throughout the study. No significant venovenous perfusion-induced systemic hyperthermia-related hemolysis was observed. Neurologic assessment showed normal brain function all 5 days.
Our venovenous perfusion-induced systemic hyperthermia system safely delivered the hyperthermia dose with no significant hyperthermia-related complications.
由于热疗可选择性杀死肺癌细胞,我们开发了一种用于晚期肺癌治疗的静脉-静脉灌注诱导全身热疗系统。我们的目标是按照良好实验室规范标准,在为期5天的绵羊存活研究中测试我们的静脉-静脉灌注诱导全身热疗系统的安全性和准确性。
我们的静脉-静脉灌注诱导全身热疗系统包括一个双腔插管(Avalon Elite,加利福尼亚州兰乔多明格斯)、一个离心泵(Bio-Pump 560;美敦力公司,明尼苏达州明尼阿波利斯)、一个热交换器(BIOtherm;美敦力灌注系统公司,明尼苏达州布鲁克林公园)和一个加热器/冷却器(改良的Blanketrol III,俄亥俄州辛辛那提市辛辛那提零下公司),在健康成年绵羊(n = 5)身上进行了测试。灌注回路用预热的血浆代用品A(百特医疗保健公司,伊利诺伊州迪尔菲尔德)灌注并排气。将校准的温度探头放置在动物鼻咽部的左右两侧、膀胱以及进出血管的血液管道中。双腔插管通过颈静脉插入上腔静脉,尖端位于下腔静脉。
根据鼻咽部和膀胱左右两侧的温度计算得出,所有绵羊均达到了治疗核心温度(42°C - 42.5°C)。加热时间为21±5分钟。治疗核心温度维持120分钟,随后进入冷却阶段(35±6分钟)以达到基线温度。所有绵羊在4小时内从麻醉中苏醒并恢复自主呼吸。动脉压、肺动脉压和中心静脉压稳定。热疗期间心率、心输出量和血糖短暂升高,但在静脉-静脉灌注诱导全身热疗结束后恢复到正常范围。在整个研究过程中,电解质、全血细胞计数和代谢酶均在正常至接近正常范围内。未观察到明显的与静脉-静脉灌注诱导全身热疗相关的溶血现象。神经学评估显示所有5天内脑功能均正常。
我们的静脉-静脉灌注诱导全身热疗系统安全地给予了热疗剂量,且未出现明显的与热疗相关的并发症。